Vir is a science-driven company guided by medical need.

Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Vir’s scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academic research.

Vir’s initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquired infections.

The company was founded by Robert Nelsen and ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Sciences, and Alta Partners. Additional investors include the SoftBank Vision Fund, Temasek, Baillie Gifford, the Alaska Permanent Fund, and select sovereign wealth funds, private individuals, family offices, and other institutional investors.

Vir is headquartered in San Francisco, California with operations in Portland, Oregon, Boston, Massachusetts, and Bellinzona, Switzerland


The Vir team is comprised of world leaders in immunology, infectious disease, and drug development. Learn more about our executive team, board of directors, and scientific advisors below.

Executive Team

George Scangos photo

George Scangos, Ph.D.

CEO & Director

Alex Bangs photo

Alex Bangs

Chief Information Officer

David Gollaher photo

David Gollaher, Ph.D.

Head of Policy and Government Affairs

Howard Horn photo

Howard Horn

Chief Financial Officer

Bolyn Hubby photo

Bolyn Hubby, Ph.D.

SVP, Research & Public-Private Partnerships

Michael Kamarck photo

Michael Kamarck, Ph.D.

Chief Technology Officer 

Lynne Krummen photo

Lynne Krummen

SVP, Regulatory & Development Program Leadership & Management

Antonio Lanzavecchia photo

Antonio Lanzavecchia, M.D.

SVP & Senior Research Fellow

Phil Pang photo

Phil Pang, M.D., Ph.D.

Chief Medical Officer

Jay Parrish photo

Jay Parrish, Ph.D.

Chief Business Officer

Irene Pleasure photo

Irene Pleasure, Ph.D.

VP, Intellectual Property & Associate General Counsel

Eric Schlezinger photo

Eric Schlezinger

Head of Human Resources

Herbert Virgin photo

Herbert “Skip” Virgin

EVP, Research & Chief Scientific Officer

Board of Directors

George Scangos photo

George Scangos, Ph.D.

CEO & Director

Kristina Burow photo

Kristina Burow


Tom Daniel photo

Tom Daniel, M.D.


Klaus Frueh photo

Klaus Frueh, Ph.D.

Director & Co-founder

Bob More photo

Bob More


Robert Nelsen photo

Robert Nelsen

Director & Co-founder

Deep Nishar Photo

Deep Nishar


Rob Perez photo

Rob Perez


Scientific Advisors

Jeff Bluestone photo

Jeff Bluestone, Ph.D.

Scientific Advisor

Frank Chisari photo

Francis V. Chisari, M.D.

Scientific Advisor

Larry Corey photo

Larry Corey, M.D.

Scientific Advisor & Co-founder

Mark Davis photo

Mark Davis, Ph.D

Scientific Advisor

Emilio Emini photo

Emilio Emini, Ph.D.

Scientific Advisor

Susanna Naggie photo

Susanna Naggie, M.D.

Scientific Advisor

Louis Picker photo

Louis Picker, M.D.

Scientific Advisor & Co-founder

George Poste photo

George Poste, DVM, Ph.D.

Scientific Advisor

Jeffrey Ravetch photo

Jeffrey V. Ravetch, M.D., Ph.D.

Scientific Advisor

Charlie Rice photo

Charles M. Rice, Ph.D.

Scientific Advisor



View All 



Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218

SAN FRANCISCO—Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The commencement of first-in-human dosing marks the first clinical use of Alnylam’s Enhanced Stabilization Chemistry-Plus (ESC+) GalNAc conjugate delivery platform and the start of Vir’s first global development program. 

Read More

Vir Biotechnology Appoints Leading Immunologist Antonio Lanzavecchia, M.D., Senior Vice President, Senior Research Fellow

SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Antonio Lanzavecchia, M.D., as Senior Vice President and Senior Research Fellow, effective immediately. Reporting to Chief Executive Officer George Scangos, Ph.D., Dr. Lanzavecchia will provide scientific leadership for Vir’s technical programs that are designed to transform the care of people with serious infectious diseases.

Read More



View All 

CAREERS at Vir Bio

View Jobs

Vir is always interested in knowing the best and the brightest talent. If you do not see a role that matches your background we encourage you to email your resume to resumes@vir.bio. This will help us find you if a new need arises that fits your experience.




499 Illinois Suite 500
San Francisco, CA 94158
email: info@vir.bio